# Sanofi ADS (SNY) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $44.24, market value $106.0 billion.

## Valuation
- **P/E (trailing): 23.5×** (5-yr avg 8.3×, 3-yr avg 9.1×). Sanofi ADS trades at 23.5× trailing earnings, well above its own five-year average of 8.3×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 8.2×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.19**. A PEG of 0.19 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.9×**. Each dollar of revenue is priced at 1.9×.
- **Price / book: 1.3×**. The shares trade at 1.3× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 11.9×**. Enterprise value is 11.9× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 9.2%**. Free cash flow equals 9.2% of the market value. Above 5% is generally attractive.
- **Earnings yield: 4.2%**. The inverse of the P/E: 4.2% of the price is earned each year.

## Profitability
- **Gross margin: 72.8%**. Sanofi ADS keeps 72.8% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 20.6%**. 20.6% of revenue is left after running the business, a healthy level in most sectors.
- **Return on equity: 10.9%**. 10.9% on shareholders' equity is solid.
- **Return on invested capital: 10.0%**. Return on all capital, debt included, is 10.0%.
- **Return on assets: 3.1%**. Each dollar of assets produces 3.1% of profit.

## Growth
- **EPS growth (1 yr): 43.8%** (3-yr -1.5%/yr, 5-yr -8.2%/yr). Earnings per share rose 43.8%.

## Financial health
- **Debt to equity: 0.20**. Debt is 0.20 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.8×**. It would take 0.8 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 13.8×**. Operating profit covers interest 13.8× over, a safe margin.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 5.47%** ($2.42 per share, trailing). Sanofi ADS yields 5.47%, an income-level yield.
- **Consecutive years of increases: 2**. 2 straight years of increases.
- **Dividend growth (5 yr): 4.8%/yr** (1-yr 8.6%). The dividend has grown 4.8% a year over five years.

## Analyst view
- **Analyst consensus: buy** (9 analysts). 9 analysts cover Sanofi ADS; the consensus is buy, with an average price target of $53.72 (+21% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 3.0%** (YTD -3.6%, 3-mo -1.7%). The shares are up 3.0% over twelve months including dividends.
- **From 52-week high: -16.0%** (8.2% above the low). Trading 16% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 48**. An RSI of 48 is neutral.
- **Beta (1 yr): 0.29** (volatility 23%). Beta of 0.29 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SNY · Page: https://foliofundamentals.com/stocks/sny

Not investment advice.